Symbiotec Pharmalab Ltd

NSE: SYMBIOTEC · Pharmaceuticals · sector

₹1,229.80NSE close 2026-10-26

Key numbers

Market cap₹7,715 cr

Price₹1,229.80

52w high / low₹1,310 / ₹934

P/E–Sector median 27.9x

P/B–Sector median 2.9x

Book value₹–

Dividend yield–Sector median 0.48%

ROE–Sector median 11.7%

ROCE–Sector median 12.3%

OPM–Sector median 14.0%

Debt / equity–Sector median 0.16x

EV/EBITDA–Sector median 18.6x

Interest cover–

Current ratio–

Sales growth 3y–Sector median +9.6%

Profit growth 3y–Sector median +13.3%

PEG–

Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.

Things to know

38.54% of the promoters' shares are pledged (12.8% of all shares).
Price ₹1,229.80 on 2026-10-26: -6.1% from the 52-week high, +31.6% from the 52-week low.

Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.

Charts

Weekly close · high ₹1,279.50 · low ₹1,024.05

Quarterly results

₹ cr	Jun 2026
Revenue	218
EBITDA	45
OPM %	20.7%
Other income	0
Net profit	14
EPS (₹)	2.24

Consolidated figures where filed. Latest quarter Jun 2026.

Profit & loss (yearly)

₹ cr	TTM
Revenue	–
EBITDA	–
Net profit	–
EPS (₹)	–
Dividend / share (₹)

Compounded growth	3 years	5 years	Last 12 months
Sales	–	–	–
Net profit	–	–	–
EPS	–	–	–
Share price	–	– (2y)	–

Shareholding

Holder	% (2026-09-30)
Promoters	33.28%
FIIs	3.79%
DIIs	33.17%
of which Mutual funds	12.18%
of which Insurance	1.07%
Public (non-institutions)	29.76%

Quarter	Aug 2026	Sep 2026
Promoters %	33.28%	33.28%

Promoter group	%
Satwani Holdings LLP	15.28%
Anil Satwani	4.37%
Kashish Satwani	4.28%
Anil Satwani	3.42%
Anil Satwani	3.42%
Sushil Satwani	1.92%
Anil Satwani	0.54%
Sunil Satwani	0.02%
Swati Sachdev	0.02%

Public holders above 1%	%
Rosewood Investments	14.07%
Business Excellence Trust Iii - India Business Excellence Fund Iii	10.24%
Mirae Asset Aggressive Hybrid Fund	6.00%
Valuequest Founders Conviction Lvf	2.92%
Think India Opportunities Master Fund Lp	2.76%
Pi Opportunities Aif V Llp	1.78%
Dymon Asia Multi-Strategy Investment (Singapore) Pte. Ltd	1.58%
Icici Prudential Smallcap Fund	1.55%
Motilal Oswal Small Cap Fund	1.45%
Vq Fastercap Fund Ii	1.03%

81,747 shareholders. Pledged: 38.54% of promoter shares.

Peers in Pharmaceuticals

Company	Market cap	P/E	P/B	ROE	ROCE	OPM	Sales 3y	Div yield
SUNPHARMA	₹4,17,478 cr	34.5x	5.0x	15.5%	18.7%	28.6%	+10.0%	0.94%
DIVISLAB	₹2,39,825 cr	82.1x	14.3x	18.4%	23.0%	34.7%	+10.8%	0.34%
TORNTPHARM	₹1,53,999 cr	72.7x	18.4x	27.3%	15.1%	32.3%	+13.3%	0.84%
ZYDUSLIFE	₹1,15,808 cr	25.9x	4.3x	17.7%	16.8%	27.2%	+16.4%	0.95%
LAURUSLABS	₹1,11,232 cr	101.6x	21.0x	22.4%	20.8%	28.0%	+4.1%	0.08%
CIPLA	₹1,09,464 cr	32.5x	3.2x	10.3%	13.2%	17.7%	+7.4%	1.18%
DRREDDY	₹1,09,460 cr	33.9x	2.9x	9.0%	10.1%	15.5%	+11.0%	0.61%
MANKIND	₹95,486 cr	46.7x	5.9x	13.4%	13.8%	25.1%	+17.7%	0.04%
AUROPHARMA	₹91,489 cr	24.9x	2.4x	10.5%	12.8%	20.0%	+10.6%	0.26%
SYMBIOTEC	₹7,715 cr	–	–	–	–	–	–	–

All 185 companies in Pharmaceuticals →

Documents

Links go to the original files on the exchange website.

About the company


Sector	Healthcare
Industry	Pharmaceuticals
Sub-industry	Pharmaceuticals
Symbol	SYMBIOTEC
BSE code	544889
ISIN	INE899I01028
Face value	₹2.0
Incorporated	–
Website	–
Plants (India / abroad)	–

Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.